Yan Xiong

This paper identifies G9a's role in SARS-CoV-2-induced pathogenesis by regulating translation of viral and host proteins, showing that G9a inhibitors can reverse disease-related proteomic changes.

This paper discovers a first-in-class PROTAC degrader for G9a/GLP, showing effective degradation and superior anticancer activity compared to existing inhibitors.

This study identifies G9a's noncanonical role in promoting translation of genes involved in hyperinflammation and lymphopenia in COVID-19, revealing therapeutic targets that counteract viral effects.

This paper introduces deschloroclozapine (DCZ), a potent and selective DREADD agonist that rapidly modulates neuronal activity and behavior in mice and monkeys.